Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.

Daniel Barretto KendlerMario Lucio AraújoRenata AlencarMaria Theresa de Souza AcciolyDaniel Alves BulzicoCencita Cordeiro de Noronha PessoaFernanda Andrade AcciolyTerence Pires de FariasFlaia Paiva Proença Lobo LopesRossana CorboMario VaismanFernanda Vaisman

Published in: Endocrine (2017)

This is the first study to show the correlation of the presence of SSTR1, detected by monoclonal immunohistochemical techniques, and better response to initial treatment and possibly better long-term clinical response in patients with MTC. In addition, these patients had low positivity rates for SSTR2, which might explain the low sensitivity of diagnostic and limited therapeutic response to octrotide based radioisotopes.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
stem cells
multiple myeloma
patient reported outcomes
mesenchymal stem cells
replacement therapy
patient reported